Drugs in MeSH Category Antitrichomonal Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Unique	TINIDAZOLE	tinidazole	TABLET;ORAL	202489-002	Oct 9, 2013	AB	RX	No	No
Chartwell Rx	TINIDAZOLE	tinidazole	TABLET;ORAL	202044-001	Apr 30, 2012	AB	RX	No	No
Chartwell Rx	TINIDAZOLE	tinidazole	TABLET;ORAL	202044-002	Apr 30, 2012	AB	RX	No	No

Market Dynamics and Patent Landscape for NLM MeSH “Antitrichomonal Agents”: exclusivity, Orange Book status, and generic/biosimilar risk

Last updated: July 8, 2026

The antitrichomonal-agent market is dominated by a small set of actives approved for Trichomonas vaginalis and, in practice, is driven by metronidazole- and tinidazole-based products, plus a limited pipeline. Patent risk concentrates in (1) legacy oral nitroimidazoles approaching or past core expiration, (2) formulation and method-of-use patent layers, and (3) local-market exclusivity (FDA exclusivity where applicable). Net: generic entry is the default trajectory in most geographies once Orange Book-listed patents and any pediatric/other exclusivities expire, with litigation acting mainly as a timing lever rather than a sustained block for most actives.

Which antitrichomonal agents are in NLM MeSH class, and what drives their market?

Answer: Commonly marketed antitrichomonal agents map to nitroimidazoles, with metronidazole and tinidazole as the core generics anchors. Market dynamics are shaped by (a) persistent STI prevalence, (b) drug cost compression, (c) guideline-driven dosing, and (d) patent-layer duration that slows only a subset of brand exits.

What are the MeSH sub-areas that typically concentrate sales and IP?

MeSH “Antitrichomonal Agents” is a pharmacologic bucket that, in operational terms, clusters:

• Nitroimidazole drugs used for trichomoniasis, with frequent global off-patent status for the base API.
• Selected branded combinations or extended-release/formulation variants in some markets.
• Narrow pipeline programs (limited new molecular entities) compared with broader STI classes.

Which commercial factors decide whether a patent “matters”?

1. Orange Book density: how many US patents list against the specific NDA for an approved strength/dosage form.
2. Exclusivity stacking: whether 5-year New Chemical Entity (NCE) or 7-year/other exclusivities apply in addition to listed patents.
3. Paragraph IV count: how often ANDA filers challenge listed patents, indicating where courts are likely to resolve “real” infringement disputes.
4. Formulation specificity: whether patents are limited to a particular release profile, excipient set, or tablet/capsule configuration.

What patents protect metronidazole, tinidazole, and other antitrichomonal actives in the US?

Answer: For most antitrichomonal agents in this class, core composition-of-matter and basic formulation patents are long expired. US protection typically shifts to late-cycle: formulation, crystalline form (if any), manufacturing process, and method-of-use tied to specific dosing regimens or patient subsets. Patent “protection” is therefore often patchy by strength and dosage form rather than spanning the entire class.

How strong is the patent estate for the typical nitroimidazole backbone?

Business pattern: Expect thin-to-moderate US patent estates for the underlying API, with the practical protection coming from:

• Last-to-expire method-of-use patents (timing-dependent).
• Formulation patents scoped to a specific controlled-release or unique dosage form.
• Process patents that can block certain manufacturing routes.

What formulation patents commonly appear for antitrichomonal products?

Common buckets for formulation or delivery patents in STI-era lifecycle management:

• Immediate-release to modified-release conversion (release profile claims).
• Tablet/capsule composition with specific binders/disintegrants/coatings.
• Particle size or polymorph/crystal habit claims when supported by stability data.
• Manufacturing process parameters (mixing, drying, compression, granulation controls).

What is the Orange Book status of antitrichomonal agents like metronidazole and tinidazole?

Answer: Base nitroimidazole oral products are predominantly off-patent in the US, with many SKUs having no active Orange Book-listed patents. Where Orange Book patents remain, they are typically strength- and dosage-form-specific and may be tied to formulation and method-of-use patents rather than the core API.

How to interpret Orange Book risk for class-level decisions?

• If the Orange Book is sparse or empty for a marketed strength, ANDA approval is usually execution risk only (bioequivalence and labeling).
• If Orange Book lists multiple patents, generic entry risk hinges on the latest-expiring patent set and the likelihood of successful Paragraph IV litigation outcomes.
• If patents are “use” patents, the labeling and intended-use carve-outs drive infringement analysis.

When does metronidazole or tinidazole lose exclusivity, and what timing controls generic entry?

Answer: Most exclusivity for classic nitroimidazoles has already lapsed. Remaining entry constraints, when present, come from last-expiring Orange Book patents and from any unexpired exclusivity tied to a newer NDA (if applicable to specific branded products or dosage forms).

What timelines matter for US market entry?

US generic timing is governed by:

• Expiration of Orange Book-listed patents (including regulatory stays).
• Any applicable FDA exclusivity windows (NCE, pediatric, other exclusivities) tied to the NDA/BLA.
• Hatch-Waxman litigation stays triggered by Paragraph IV filings.

What drives “effective exclusivity” beyond nominal expiration?

• Narrow method-of-use claims that keep a generic labeling “off-limits” longer than composition claims.
• Settlement agreements that delay launch date even when patents are arguably weak.
• Multiple patents spanning different aspects of product performance and dosing.

Which companies are challenging patents for antitrichomonal agents, and how often do settlements delay launches?

Answer: In antitrichomonal oral nitroimidazole categories, generic challengers typically include established ANDA filers that routinely file Paragraph IV certifications on older assets. Settlements are common where at least one listed patent is still within the active litigation window, producing a predictable “carve-out” delay even for legacy drugs.

What litigation patterns are most common in this class?

• Early-stage procedural outcomes (dismissals, covenant not to sue, consent judgments) that end with delayed launch.
• Label carve-outs tied to method-of-use patents.
• Design-around of formulation where claims are specific to excipient/coating or release profile.

What patent litigation affects generic entry risk for antitrichomonal agents?

Answer: For most class members, the key impact comes from whether an ANDA filer challenges the last-expiring Orange Book patents. If litigation ends in a court decision of non-infringement or invalidity, generic entry can accelerate. If a brand settles, launch timing is often delayed to a mutually agreed date.

How to assess infringement risk when patents target dosing instructions?

Method-of-use and labeling patents require a generic to either:

• Avoid infringing labeling language (carve-out), or
• Include labeling that induces use within claimed boundaries, which can trigger infringement.

How to assess infringement risk when patents target formulation?

Formulation/process patents can be harder for generic developers to “label around,” so infringement disputes tend to focus on:

• Composition differences in excipients and coatings.
• Manufacturing process validation.
• Whether the generic’s release profile or stability claims match the patented profile.

What generic entry risks exist for antitrichomonal agents in the US and other major markets?

Answer: Default risk is high for older metronidazole/tinidazole oral products because most base-product patents are expired. Residual entry risk is concentrated in:

• Remaining Orange Book-listed patents for specific strengths or dosage forms,
• Any newer branded formulation versions,
• Settlement-delayed launches.

What changes the risk profile by region?

• US (FDA/Hatch-Waxman): Entry is directly tied to Orange Book listings and any Paragraph IV litigation outcomes.
• EU/UK (SPC and national patent enforcement): Even if the base API is off-patent, Supplementary Protection Certificates or national patents can delay.
• Other geographies: Where formal patent linkage is weaker, enforcement timing is more dependent on injunction availability and local litigation pace.

How does the antitrichomonal patent landscape compare with other STI drug classes?

Answer: Compared with HIV, HBV, and many oncology and autoimmune categories, antitrichomonal agents show:

• Fewer active development programs.
• Concentrated IP estates around older, commoditized oral therapies.
• Lower probability of pipeline-driven “evergreening” that changes the market structure.

What does this mean for licensing and investment?

• Licensing opportunities are more likely to target specific formulation/process improvements or new combinations than the core API.
• Transaction value depends more on unexpired patents tied to specific product lines than on class-level IP.

What formulations are protected for antitrichomonal agents, and which delivery systems matter?

Answer: Protection tends to map to oral solid dosage formats (tablets/capsules) with either immediate-release or modified-release profiles. Delivery systems that affect release kinetics, stability, and bioavailability are the most patent-sensitive segments.

Which dosage forms are most often subject to patent layers?

• Immediate-release tablets/capsules with specific composition and manufacturing controls.
• Modified-release or dosage-form variants (when present) that create distinct claim scopes.
• Fixed-dose combinations, if any, where method-of-use and composition both can be claimed.

What method-of-use patents can delay generics for antitrichomonal agents?

Answer: Method-of-use patents can delay generic launches when the generic labeling is tied to the claimed regimen (dosing schedule, patient subset, or therapeutic endpoint).

Typical claim structures for method-of-use

• Specific dosing regimens for Trichomonas vaginalis.
• Use in special populations (pregnancy timing windows, recurrent infection protocols).
• Sequencing relative to other agents (when the regimen is claimed).

What does FDA regulatory status imply for exclusivity and label carve-outs?

Answer: FDA labeling controls infringement risk for use patents. When brands and ANDA filers settle, labeling carve-outs often reflect the court’s or settlement’s interpretation of the claimed regimen.

What drives labeling differences in practice?

• Different indications or dosage language for the same active.
• Switching between “treatment of trichomoniasis” and “reduces transmission” language where claim scopes diverge.
• Avoidance of patient population language that matches a method-of-use claim.

Key Takeaways

• Antitrichomonal agents in MeSH are dominated by legacy nitroimidazoles with largely expired base-IP, shifting protection to strength-specific Orange Book patents tied to formulation or method-of-use.
• US exclusivity timing is typically governed by last-expiring listed patents and any litigation-triggered regulatory stays rather than by broad class exclusivity.
• Generic entry risk is generally high for older metronidazole/tinidazole oral products; residual risk concentrates where Orange Book lists active patents for specific dosage forms or where settlements delay launches.
• Patent strength for this class is typically moderate to low at the API level and higher for formulation/process or narrow labeling-driven method-of-use claims.

FAQs

1) Which nitroimidazole formulations in antitrichomonal therapy still face active US Orange Book protection?
Answer: Only specific branded strengths/dosage forms typically carry active listings; base actives are generally off-patent.

2) How do Paragraph IV challenges usually play out for older antitrichomonal drugs?
Answer: They tend to target the last-expiring Orange Book patents, with settlements often controlling launch timing.

3) Do method-of-use patents for Trichomonas treatment block ANDA approval, or only launch timing?
Answer: They can delay launch via labeling carve-outs or litigation over whether the generic’s proposed labeling infringes.

4) Are there meaningful biosimilar risks in antitrichomonal agents?
Answer: The class is predominantly small-molecule nitroimidazoles, so biosimilar risk is usually not a primary driver.

5) What is the practical licensing target in this MeSH class?
Answer: Late-cycle formulation or process IP and any new fixed-dose combinations, not the legacy API.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. (accessed via Orange Book database).
2. NLM. Medical Subject Headings (MeSH): Antitrichomonal Agents. (accessed via MeSH database).